Initial Experience with Generic Letermovir [Anvimo] in Preventing Cytomegalovirus Reactivation in Hematopoietic Stem Cell Transplant Recipients Who Are at a High Risk of Infection. (TCT-ASTCT-CIBMTR 2026) - Jan 8, 2026 - Abstract #792; 599; Pres time: Feb 5, 2026; 06:30 PM - 08:00 PM; Location: Hall AB (Salt Palace Convention Center); "Anvimo was started following engraftment at a dose of 240 mg [with cyclosporine] or 480 mg till Day 100...Majority of patients with reactivation received ganciclovir as pre-emptive therapy and cleared the viremia... Generic Letermovir [Anvimo] in useful in reducing the incidence of CMV reactivation especially in haplo-identical transplants. More long-term data is needed to look at secondary reactivation and survival. 1."
Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Immunology • Infectious Disease • Transplantation
|
|
Biju George, MD, DM 1; Shubham George, MD 2; Nutan George, MD DM 2; Mithun Prakash Abraham, MD DM 2; Yamuna Naik, MD DM 1; Venkatachalam RM, MD DM 2; Sujith Karumathil, MD DM 2; Sharon Lionel, MD, DM 1; Uday Kulkarni, MD, DM 1; Anu Korula, MD, DM 1; Vikram Mathews, MD, DM 1; Aby Abraham, MD, DM 1
|